StreetInsider.com News Articles

China SXT Pharmaceuticals announces 1-for-80 share consolidation

Wed, 05 Aug 2026 09:00:10 -0400

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced a 1-for-80 share consolidation of its Class A and Class B ordinary shares, effective August 10, 2026, according to a press release from the Taizhou, China-based company.

Prior to the consolidation, 105,704,077 Class A ordinary shares are issued and outstanding. Following the consolidation, approximately 1,321,301 Class A ordinary shares will be outstanding, with every 80 shares combined into one share. Fractional shares will be rounded up to the next whole share.

The company's Class A ordinary shares will continue trading on the Nasdaq Stock Market under the ticker symbol "SXTC" on a post-consolidation basis beginning

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Wed, 05 Aug 2026 09:00:00 -0400

TAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company”), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, and Class B ordinary shares no par value per share, at a ratio of 1-for-80, effective on August 10, 2026 (the “Share Consolidation”). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on August 10, 2026. Upon the market opening on August 10, 2026, the Company’s Class A

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Wed, 05 Aug 2026 09:00:00 -0400

China SXT Pharmaceuticals closes $9M registered direct offering

Fri, 24 Jul 2026 17:30:08 -0400

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has closed a registered direct offering raising $9 million in gross proceeds, according to a press release from placement agent Univest Securities, LLC.

The company sold 4,500,000 units to institutional investors at $2.00 per unit. Each unit consists of one Class A ordinary share and one warrant with an exercise price of $3.20 per share. The warrants are immediately exercisable upon issuance and expire one year from the issuance date.

Univest Securities, LLC served as the sole placement agent for the offering, which was made pursuant to a shelf registration statement on Form F-3 declared effective

China SXT Pharmaceuticals closes $9M registered direct offering

Fri, 24 Jul 2026 17:30:08 -0400

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has closed a registered direct offering raising $9 million in gross proceeds, according to a press release from placement agent Univest Securities, LLC.

Univest Securities, LLC served as the sole placement agent for the offering, which was made pursuant to a shelf registration statement on Form F-3 declared effective

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Form 6-K China SXT Pharmaceutical For: Jul 24

Fri, 24 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260724/26813864.html

Form 6-K China SXT Pharmaceutical For: Jul 24

Fri, 24 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260724/26813864.html

Form 424B5 China SXT Pharmaceutical

Fri, 24 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260724/26811268.html

Form 424B5 China SXT Pharmaceutical

Fri, 24 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260724/26811268.html

China SXT Pharmaceuticals launches $9M registered direct offering

Thu, 23 Jul 2026 08:45:13 -0400

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a registered direct offering of 4,500,000 units at $2.00 per unit, with expected gross proceeds of approximately $9 million before placement agent fees and other expenses.

Each unit consists of one Class A ordinary share and one warrant with an exercise price of $3.20 per share. The warrants are immediately exercisable upon issuance and expire one year from the date of issuance.

The offering is being made pursuant to a shelf registration statement on Form F-3 previously filed with the U.S. Securities and Exchange Commission, which became effective on December 1, 2025. Univest Securities, LLC

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

Thu, 23 Jul 2026 08:45:00 -0400

TAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4,500,000 units (each, a “Unit”), consisting of one Class A ordinary share of the Company, no par value per share (each, a “Class A ordinary share”), and one common warrant (each, a “Warrant”), at a purchase price of $2.00 per Unit in a registered direct offering.

Each of the Warrants will have an exercise price of

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

Thu, 23 Jul 2026 08:45:00 -0400

Each of the Warrants will have an exercise price of

China SXT Pharmaceuticals (SXTC) files for 157.5M share offering by selling stockholders

Tue, 07 Jul 2026 16:32:57 -0400

China SXT Pharmaceuticals (NASDAQ: SXTC) has filed for up to 157,500,000 share offering by selling stockholders.

China SXT Pharmaceuticals (SXTC) files for 157.5M share offering by selling stockholders

Tue, 07 Jul 2026 16:32:57 -0400

China SXT Pharmaceuticals (NASDAQ: SXTC) has filed for up to 157,500,000 share offering by selling stockholders.

Form F-3 China SXT Pharmaceutical

Tue, 07 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260707/26742185.html

Form F-3 China SXT Pharmaceutical

Tue, 07 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260707/26742185.html

Form 6-K China SXT Pharmaceutical For: Jul 06

Mon, 06 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260706/26735984.html

Form 6-K China SXT Pharmaceutical For: Jul 06

Mon, 06 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260706/26735984.html

Form 20-F China SXT Pharmaceutical For: Mar 31

Wed, 01 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260701/26721303.html

Form 20-F China SXT Pharmaceutical For: Mar 31

Wed, 01 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260701/26721303.html

Form 6-K China SXT Pharmaceutical For: Jun 01

Mon, 01 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260601/26584935.html